mecf
common
diseas
unknown
etiolog
character
postexert
malais
pem
type
fatig
cognit
disturb
unrefresh
sleep
autonom
nerv
dysfunct
characterist
comorbid
see
eg
ref
often
start
infect
strong
tendenc
remain
chronic
condit
mecf
diagnost
criteria
gradual
becom
stringent
see
eg
ref
base
somat
often
selfreport
symptom
although
often
use
interchang
studi
use
cdc
also
call
fukuda
criteria
mainli
use
term
cf
use
canada
intern
consensu
criteria
use
term
creat
ambigu
may
explain
contradict
result
far
specif
laboratori
test
mecf
diagnosi
recent
committe
recommend
new
name
mecf
system
exhaust
intoler
diseas
seid
diagnost
criteria
emphas
pem
central
mecf
symptom
diseas
entiti
mecf
uncontroversi
like
mani
time
medic
histori
psychiatr
somat
explan
compet
recent
critic
review
emphas
psychiatr
aspect
state
convinc
pathogenesi
model
cf
howev
review
forward
evid
somat
origin
diseas
accumul
research
perspect
import
patient
diagnos
use
strict
criteria
thorough
clinic
examin
necessari
matter
sophist
analys
studi
patient
select
ambigu
case
fatigu
import
distinguish
mecf
fatigu
type
fatigu
burnout
syndrom
depress
see
eg
ref
mecf
repetit
physic
mental
exert
reveal
object
evid
fatig
exertionelicit
fatigu
pem
requir
diagnosi
mecf
use
canadian
criteria
intern
consensu
seid
use
cdc
criteria
although
term
mecf
encompass
cf
builtin
ambigu
cover
much
current
studi
oper
judg
best
avail
concept
fatigu
similar
pem
also
occur
syndrom
ss
primari
biliari
cholang
also
name
primari
biliari
cirrhosi
pbc
system
lupu
erythematosu
sle
relat
mecf
similar
condit
gulf
war
ill
gwi
uncertain
see
eg
ref
howev
recent
studi
describ
laboratorybas
distinct
two
ill
recent
mecf
report
brought
optim
nation
institut
health
us
announc
priorit
diseas
cornerston
studi
pem
effect
immunosuppress
treatment
although
substanti
phase
iii
trial
sever
partli
compet
explanatori
model
mecf
exampl
autoimmun
chronic
infect
energi
metabol
defect
imbal
autonom
nervou
system
andor
hormon
psychosomat
dysfunct
laboratoryori
review
present
overview
recent
find
attempt
bring
substanti
portion
mecf
symptom
diseas
histori
one
explanatori
model
model
draw
analog
establish
autoimmun
diseas
even
much
remain
understood
base
clinic
experi
recent
immunometabol
result
clue
research
given
tabl
separ
statement
text
propos
pathogenet
model
reminisc
current
think
pathogenesi
autoimmun
genet
predispos
person
expos
success
infect
b
eg
gastrointestin
dysbiosi
irrit
bowel
syndrom
ib
airway
microb
carri
epitop
mimick
human
selfepitop
microb
activ
autoreact
b
cell
produc
socal
natur
antibodi
nonrearrang
germ
line
immunoglobulin
gene
autoreact
b
cell
may
delet
persist
state
anergi
c
proport
b
cell
remain
spleen
lymph
node
memori
igm
iga
igg
b
cell
individu
differ
time
extent
encount
autoreact
elicit
microb
encount
postul
give
rise
autoantibodi
e
key
enzym
energi
metabol
henc
caus
defect
aerob
energi
metabol
pem
central
symptom
mecf
other
fibromyalgia
fm
yet
other
postur
orthostat
tachycardia
syndrom
pot
comorbid
autoimmun
event
independ
occur
order
cooper
effect
may
follow
rather
specif
order
f
upper
case
letter
refer
stage
figur
thu
basic
properti
mecf
patient
would
defect
toler
coupl
chanc
exposur
microb
carri
relev
mimick
autoantigen
epitop
italic
text
figur
show
hypothet
explan
event
behind
mecf
known
function
microb
gut
train
within
immun
system
recogn
react
correctli
microb
includ
bacteria
virus
come
outsid
correct
reaction
includ
among
thing
anergi
unrespons
microbi
antigen
crossreact
selfantigen
known
mecf
patient
often
ib
ib
also
modifi
gut
flora
less
symptomat
gut
dysbiosi
may
also
occur
addit
also
occasion
epitheli
barrier
leakag
gut
microb
reason
assum
innat
mucos
immun
defens
breach
peripher
toler
mainten
train
function
gut
flora
disturb
normal
mucos
immun
system
must
maintain
toler
harmless
foreign
antigen
includ
food
commens
microb
present
antigen
mucosa
often
lead
toler
microleakag
toler
may
function
properli
lead
loss
checkpoint
normal
prevent
develop
autoreact
profil
b
cell
subpopul
differ
mecf
compar
control
factor
behind
could
new
memori
b
cell
autoreact
normal
would
sort
aris
persist
bodi
expos
new
infect
b
cell
could
produc
antibodi
react
microb
autoantigen
autoantibodi
cell
recogn
selfpeptid
damag
cell
carri
autoantigen
socal
mimicri
antigen
similar
theori
behind
autoimmun
diseas
part
explan
mecf
would
disturb
gut
flora
microleakag
gut
left
side
figur
written
genet
predisposit
compat
increas
frequenc
mecf
certain
famili
like
mani
common
diseas
mecf
could
depend
inherit
environ
hypothesi
correct
tendenc
autoreact
would
aris
gradual
via
chang
gut
flora
microleakag
gut
decis
immun
event
autoimmun
lead
mecf
would
aris
shown
figur
prerequisit
autoimmun
would
aris
gradual
b
cell
tendenc
autoimmun
would
aris
recur
microleakag
across
mucos
barrier
gastrointestin
tract
induc
state
chronic
inflamm
normal
contact
gut
microb
immun
system
occur
gutmucosa
interphas
central
toler
often
develop
elimin
autoreact
b
cell
howev
proport
autoreact
b
cell
remain
kept
unrespons
anerg
microleakag
mucos
barrier
bypass
toler
may
maintain
autoreact
b
cell
activ
differenti
autopath
b
cell
frequenc
ib
alter
microbiom
extent
microleakag
studi
mecf
attempt
find
autoreact
b
cell
find
origin
evolut
made
mayb
possibl
trace
evolv
systemat
sequenc
antigenbind
structur
paratop
idiotyp
germ
line
antigut
microb
autoimmun
clone
dna
modif
methyl
promot
gene
associ
immun
cell
regul
glucocorticoid
receptor
atpas
receptor
respect
report
differ
mecf
control
dna
methyl
depend
onecarbon
metabol
mecf
chang
record
although
reason
hypomethyl
specul
upon
interest
combin
action
vitamin
folic
acid
play
fundament
role
provid
methyl
group
hundr
substrat
variou
elementari
cell
process
see
section
autoimmun
explain
energi
metabol
disturb
pem
recent
rnaseq
studi
specif
rna
express
mecf
compar
healthi
control
chronic
diseas
anoth
express
studi
promin
differenti
express
gene
control
rna
translat
cytoplasm
andor
mitochondria
differenti
express
gene
crucial
tcell
activ
innat
respons
virus
also
describ
cf
novel
angl
report
pattern
cerebrospin
fluid
csf
blood
anoth
kind
rna
small
regulatori
rna
differ
mecf
gwi
control
anoth
pattern
found
fm
pathophysiolog
role
small
regulatori
rna
still
uncertain
find
indic
addit
level
pathophysiolog
regul
also
could
provid
diagnost
use
biomark
prerequisit
call
diseas
chronic
durat
least
month
often
mean
one
abl
take
sampl
period
diseas
commenc
common
situat
patient
rememb
mecf
start
infect
often
infecti
mononucleosi
im
gener
virosislik
diseas
acut
infect
fever
myalgia
swollen
lymph
node
andor
cough
subsid
malais
fatig
remain
accord
literatur
approxim
mecf
case
start
rather
abruptli
way
other
gradual
debut
natur
histori
diseas
studi
systemat
case
mecf
appear
epidem
sever
case
deriv
common
index
case
even
epidem
outbreak
uncommon
indic
diseas
might
contagi
epidemiolog
studi
need
abund
evid
infect
trigger
chronic
fatigu
gener
sens
often
manifest
fatig
tabl
neg
evid
also
exist
evid
inconclus
whether
instanc
postinfecti
fatig
ident
properti
eg
fulfil
criteria
pem
mecf
chronic
etc
systemat
investig
infect
trace
patient
histori
direct
detect
microb
detect
antibodi
microb
see
howev
ref
often
happen
spous
afflict
would
advoc
transmiss
factor
rather
inherit
viru
ebv
seem
frequent
trigger
mecf
also
refer
postvir
fatigu
glandular
fever
also
call
im
frequent
caus
ebv
reason
specif
laboratori
test
im
mono
test
base
heterophil
antibodi
bind
carbohydr
antigen
nonhuman
erythrocyt
infecti
trigger
mecf
investig
posit
mono
test
provid
often
record
marker
infect
often
diagnos
object
ebv
belong
herp
viru
famili
infect
remain
latent
b
cell
primari
infect
ebv
trigger
massiv
activ
multipl
b
cell
clone
secret
monoclon
antibodi
code
immunoglobulin
heavi
light
igh
igl
chain
gene
uniqu
variabl
immunoglobulin
heavi
chain
variabl
ighv
iglv
gene
socal
complementaritydetermin
region
result
polyclon
b
cell
stimul
massiv
releas
natur
antibodi
includ
autoreact
antibodi
besid
b
cell
growth
stimul
ebv
stimul
product
one
two
chain
tolerancecontrol
heterodim
cytokin
thu
ebv
deepli
influenc
immun
function
ebv
also
code
antigen
highli
repetit
structur
eg
repeat
may
sourc
antigen
mimicri
develop
autoreact
b
cell
growth
stimul
antigen
mimicri
make
ebv
prime
suspect
induc
autoreact
correl
occurr
im
autoimmun
diseas
ms
sle
ebv
involv
frequent
reactiv
latent
ebv
defect
cell
nk
cell
surveil
mechan
viru
clear
presenc
ebv
immun
respons
compar
mecf
ms
sle
see
ref
summar
ebv
especi
interest
facilit
autoreact
autoantibodi
may
origin
mimicri
ebv
antigen
selfantigen
ebv
ubiquit
viru
ebv
stimul
thousand
b
cell
produc
thousand
differ
antibodi
uniqu
antigenbind
site
often
occur
elicit
factor
trigger
mecf
case
refer
postvir
fatigu
mention
stimul
growth
wide
varieti
b
cell
viral
protein
give
rise
autoantibodi
transmiss
microbi
properti
mecf
case
sporad
howev
record
outbreak
healthi
mecf
patient
contact
develop
symptom
diseas
form
mecf
outbreak
mecf
indic
transmiss
agent
mani
observ
support
condit
similar
mecf
occur
approxim
q
fever
infect
bacterium
coxiella
burnetii
often
occur
outbreak
q
fever
unevenli
spread
throughout
world
mecf
widespread
q
fever
therefor
unlik
common
caus
mecf
global
chronic
postinfecti
fatiguefatig
reminisc
pem
occur
number
lifethreaten
viru
infect
tabl
much
antigen
similar
infect
agent
mani
infect
fundament
challeng
reorgan
immun
system
give
rise
persist
perhap
autoimmun
malfunct
state
note
number
mecf
case
trigger
sever
zoonot
infect
ebola
must
small
global
scale
besid
im
mild
respiratori
infect
like
caus
mycoplasma
chlamydia
gener
infect
due
parvoviru
herp
mention
although
diagnost
evid
strong
although
much
remain
unclear
role
infect
autoimmun
understood
diseas
known
antigen
challeng
trigger
autoimmun
diseas
infect
vaccin
surprisingli
often
brain
target
autoimmun
tabl
addit
commonli
known
microb
viru
bacteria
protozoa
larg
number
new
one
discov
last
year
mani
virus
caus
known
diseas
need
keep
eye
microb
mayb
among
precipit
mecf
exampl
infect
elicit
autoimmun
microbi
antigen
mimic
epitop
human
cell
microbi
epitop
may
either
small
molecul
like
lipid
ad
protein
posttransl
randomli
similar
sequenc
repetit
sequenc
motif
highli
conserv
antigen
structur
exampl
former
mechan
posttransl
antigen
modif
pbc
antibodi
direct
small
fatti
acid
molecul
lipoic
acid
ad
posttransl
protein
pyruv
dehydrogenas
pdh
enzym
complex
pdh
part
energi
produc
machineri
surfac
mitochondria
govern
transit
glycolysi
anaerob
energi
metabol
tricarboxyl
acid
cycl
respiratori
chain
aerob
energi
metabol
occur
insid
mitochondria
lipoyl
posttransl
modif
also
occur
bacteria
novosphingobium
gut
infect
novosphingobium
possibl
caus
pbc
pbc
patient
pem
reminisc
pem
mecf
likewis
periodont
infect
aggregatibact
citrullin
well
human
protein
may
provid
final
trigger
rheumatoid
arthriti
exampl
latter
mechan
conserv
epitop
famili
highli
conserv
protein
present
human
microb
call
heat
shock
protein
hsp
antibodi
hsp
occur
mani
often
studi
autoimmun
diseas
exampl
ms
sle
found
higher
frequenc
level
antibodi
specif
portion
mecf
patient
even
though
mitochondri
protein
unknown
antibodi
influenc
mitochondri
function
sever
autoantibodi
found
mecf
comorbid
tabl
circumstanti
evid
mecf
autoimmun
condit
especi
interest
result
increas
frequenc
antibodi
certain
hormon
receptor
found
sever
mecf
symptom
may
explain
receptor
interfer
autoantibodi
autoimmun
condit
patholog
autoantibodi
erron
activ
mutat
b
cell
root
evil
figur
studi
detail
one
envisag
larg
scale
sequenc
immunoglobulin
gene
variabl
domain
clone
defin
aberr
specif
autoreact
characterist
variat
b
cell
subset
describ
mecf
studi
systemat
time
point
diseas
manifest
mecf
start
larg
frequenc
autoantibodi
patient
condit
prefer
measur
simultan
antigen
matrix
mayb
autoimmun
biomark
could
use
mecf
diagnosi
immun
system
engag
mecf
sever
studi
found
chang
cytokin
pattern
blood
csf
express
cytokin
gene
especi
exercis
concomit
increas
reactiv
oxygen
speci
ro
level
decreas
concentr
often
connect
flare
acut
exacerb
mecf
symptom
difficulti
cytokin
pattern
tabl
inher
variabl
cytokin
profil
may
differ
differ
stage
diseas
perman
dysregul
cytokin
plasma
also
report
see
tabl
correl
diseas
durat
seen
metaanalysi
show
increas
level
plasma
mecf
versu
control
consist
find
cytokin
csf
also
derang
mecf
tabl
compil
recent
public
cytokin
abnorm
mecf
recent
metaanalysi
conclud
mani
report
find
reproduc
could
reflect
differ
level
physic
activ
volatil
natur
cytokin
level
methodolog
problem
collect
handl
prepar
sampl
could
also
heterogen
within
mecf
group
blur
pattern
see
eg
ref
whether
cytokin
chang
exercis
peculiar
mecf
relat
subject
recent
metaanalysi
conclud
complement
factor
split
product
oxid
stress
marker
leukocyt
express
tolllik
receptor
gene
reproduc
differ
control
mecf
howev
may
subgroup
within
mecf
group
radic
differ
reaction
exercis
clearcut
differ
gene
express
exercis
mecf
patient
pot
comorbid
found
activ
socal
natur
killer
cell
also
chang
mecf
howev
neg
report
came
recent
latter
may
due
methodolog
differ
kind
immun
chang
cytokin
immun
cell
activ
potenti
biomark
studi
toler
induct
major
properti
gut
mucos
immun
system
special
kind
helper
cell
treg
mediat
mucos
toler
anergi
toler
b
cell
clone
via
may
coincid
chang
level
serum
consist
cytokin
chang
mecf
versu
control
tabl
defect
toler
develop
could
principl
detect
tendenc
develop
autoimmun
diseas
mecf
comorbid
mecf
better
studi
autoimmun
disord
ss
sle
multipl
sclerosi
indic
fatig
may
may
relat
pem
mecf
occur
major
symptom
autoimmun
mitochondri
infecti
diseas
immunostimul
eg
staphylococc
vaccin
theoret
could
induc
toler
autoepitop
involv
mecf
pathogenesi
report
effect
mecf
doubleblind
studi
symptom
relief
parallel
antistaphylococc
antibodi
presenc
argu
impair
develop
toler
autoepitop
microbi
origin
mecf
studi
need
strong
argument
b
cellmedi
autoimmun
mecf
rituximaab
effect
around
patient
improv
lag
period
rituximab
monoclon
antibodi
direct
surfac
antigen
express
major
b
cell
kill
antibodi
bind
howev
recent
phase
iii
trial
statist
signific
effect
observ
mella
person
commun
result
trial
publish
known
whether
due
major
placebo
minor
rituximab
effect
mainli
present
b
cell
neither
express
immatur
b
cell
antibodi
produc
cell
plasmablast
plasma
cell
part
problem
may
subject
estim
symptom
prone
overestim
placebo
effect
futur
doubleblind
studi
treatment
object
symptom
measur
use
larger
extent
anoth
confound
factor
may
heterogen
within
mecf
patient
although
diagnos
accord
canada
criteria
detail
studi
strongli
recommend
unpublish
phase
ii
studi
shown
improv
mecf
patient
treatment
unspecif
immunosuppress
cyclophosphamid
fluge
person
commun
anoth
sign
autoimmun
contribut
mecf
autoimmun
depend
autoantibodi
erron
activ
b
cell
root
evil
chronic
immun
stimul
increas
risk
b
cell
lymphoma
happen
mani
autoimmun
diseas
accord
autoimmun
hypothesi
mecf
present
cf
patient
greater
risk
b
cell
nonhodgkin
lymphoma
particular
margin
zone
lymphoma
ci
compar
sex
age
match
control
summari
evid
autoimmun
mecf
indirect
circumstanti
rest
effect
immunosuppress
although
unsubstanti
doubleblind
trial
comorbid
known
autoimmun
thyroid
thyroid
possibl
autoimmun
fm
pot
ib
probabl
improv
immunostimul
increas
frequenc
certain
autoantibodi
b
cell
lymphoma
criteria
autoimmun
direct
transfer
diseas
antibodi
indirect
transfer
diseas
cell
scid
mice
induct
diseas
autoantigen
identif
antibodi
within
lesion
genet
predisposit
autoantibodi
selfreact
cell
genet
predisposit
increas
frequenc
autoantibodi
partial
fulfil
much
work
remain
number
report
indic
metabol
disturb
indic
mitochondri
dysfunct
mecf
evid
point
defect
aerob
energi
metabol
aerob
energi
metabol
tca
respiratori
chain
give
around
higher
yield
atp
per
glucos
molecul
anaerob
metabol
similar
pbc
model
autoantibodi
mediat
energi
blockad
analog
pbc
igg
found
energi
inhibitori
circul
energi
inhibitor
found
mecf
although
molecular
natur
unknown
demonstr
inhibitor
potenti
explain
diseas
creat
effici
diagnost
test
would
logic
like
pbc
circul
inhibitor
turn
immunoglobulin
presum
direct
mitochondri
protein
import
research
task
compar
pem
pbc
pem
mecf
pemlik
fatig
diseas
fibromyalgia
common
comorbid
mecf
also
occur
sever
establish
autoimmun
condit
delin
mecf
fm
sometim
straightforward
fm
muscl
display
metabol
abnorm
reminisc
observ
mecf
besid
comorbid
seem
common
myalgia
muscl
metabol
abnorm
increas
frequenc
autoantibodi
distinct
pem
cognit
disturb
aspect
condit
defici
energi
suppli
may
also
caus
cognit
disturb
mecf
elicit
physic
mental
activ
analog
accumul
lactat
serum
muscl
exercis
increas
concentr
lactat
csf
found
mecf
relat
condit
gwi
mecfsspecif
chang
csf
proteom
includ
accumul
complement
compon
sign
antibodi
activ
also
describ
homocystein
part
onecarbon
metabol
report
derang
mecf
patient
perhap
compens
energi
metabol
disturb
homocystein
level
csf
wide
use
marker
reduc
cognit
investig
homocystein
vitamin
csf
patient
fulfil
criteria
fm
chronic
fatigu
syndrom
carri
comparison
larg
healthi
control
group
eleven
patient
studi
increas
homocystein
level
csf
although
blood
level
usual
increas
level
appear
gener
low
high
csfhomocystein
low
level
correl
significantli
rate
mental
fatigu
result
time
interpret
suggest
block
inflow
blood
brain
barrier
andor
folic
acid
derang
onecarbon
metabol
support
year
experi
vitamin
treatment
mecf
patient
tend
diminish
impair
cognit
brain
fog
immedi
evid
onecarbon
metabol
pathway
would
chang
block
aerob
energi
product
genesi
metabol
aberr
mecf
studi
state
onecarbon
metabol
also
profound
epigenet
consequ
dna
histon
methyl
depend
avail
sadenosylmethionin
flare
central
event
exercis
account
much
malais
pem
link
mitochondri
dysfunct
innat
immun
dysregul
suggest
recent
immunometabol
find
demonstr
energi
produc
organel
mitochondria
peroxisom
coupl
via
mitochondri
antivir
signal
protein
signal
molecul
inflammasom
orchestr
releas
inflammatori
cytokin
anoth
sign
mitochondri
derang
mecf
occurr
ro
serum
measur
increas
thiobarbitur
acid
reactiv
substanc
decreas
reduc
ascorb
acid
test
may
also
becom
part
biomark
panel
mecf
recent
shown
oxid
critic
cystein
residu
pyruv
kinas
one
enzym
pyruv
dehydrogenas
complex
pdc
lead
block
pyruv
product
potenti
mimick
autoimmun
block
pdc
activ
thu
although
pattern
metabol
chang
mecf
compat
pdh
block
blue
x
figur
possibl
autoimmun
origin
block
could
also
caus
ro
frequent
increas
mecf
ro
produc
four
place
cell
nadph
oxidas
figur
peroxisom
respiratori
chain
complex
iii
ro
product
evok
starvat
respiratori
complex
malfunct
ro
influenc
glutathion
level
indirectli
whole
onecarbon
metabol
could
key
player
mecf
pathogenesi
origin
pathobiolog
ro
mecf
investig
shown
tabl
much
work
remain
autoimmun
natur
mecf
consid
establish
even
mecf
autoimmun
origin
metabol
block
autoantibodi
hormon
receptor
import
pathogenesi
mechan
behind
flare
exercis
obscur
mayb
mitochondri
defect
lead
increas
activ
innat
immun
network
disturb
onecarbon
metabol
may
may
relat
disturb
transit
glycolysi
tca
cycl
indic
wider
metabol
derang
block
pdh
would
expect
lead
sever
paper
hormon
includ
glucocorticoid
transient
receptor
potenti
channel
hormon
receptor
mecf
conceiv
part
autonom
dysfunct
explain
way
mecf
challeng
patient
medic
research
ethic
public
health
societi
intensifi
hunt
scientif
evid
explain
mecf
larg
consequ
mani
thousand
peopl
mani
publish
result
need
repetit
shown
articl
sign
autoimmun
energi
metabol
defici
involv
diseas
increas
hypothet
logic
path
gastrointestin
tract
dysbiosi
format
pathogen
autoimmun
b
cell
inhibit
energi
product
defici
cognit
flare
cytokin
product
delin
natur
histori
indic
mani
case
infect
elicit
worsen
autoimmun
recent
intensifi
research
mecf
yield
mani
biomark
candid
mention
studi
main
consequ
work
proposit
logic
somat
explanatori
model
mecf
refut
howev
like
virtual
autoimmun
diseas
explanatori
model
sever
tent
step
need
explor
elucid
molecular
natur
circul
metabol
inhibitor
mecf
central
question
turn
immunoglobulin
may
directli
yield
diagnost
use
biomark
explan
mechan
underli
mecf
risk
give
hypothet
unifi
explan
studi
hypothesi
perceiv
fact
influenc
percept
diseas
contact
mecf
patient
care
convinc
us
handl
uncertainti
hypothes
involv
without
hypothes
direct
acquisit
knowledg
mecf
jb
conceiv
paper
wrote
cgg
ad
substanti
part
especi
regard
clinic
aspect
ae
particip
write
write
book
mecf
comprehens
knowledg
valuabl
mr
particip
write
concentr
check
refer
ar
contribut
substanti
especi
regard
immunolog
aspect
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
